These drugs work similarly but differ in dosage and specific indications (uses). Research suggests that tirzepatide is more ...

The FDA updated its database of drugs in shortage to remove tirzepatide, which had sat on that list – along with related ...

Poor purity can cause patients to experience fever, chills, nausea, skin irritation, infections and low blood pressure.

Peptide companies' are creating knock-off versions of these drugs that have not been approved by the FDA and contain ...

There’s a war brewing over blockbuster weight loss medications — and patients are now getting caught in the crossfire.

A trade organization representing compounding pharmacies that make unbranded versions of the weight loss drugs Mounjaro and ...

Federal regulators shook up a rapidly growing pharmaceutical marketplace when they announced that tirzepatide, the active ingredient in Eli Lilly’s Mounjaro and Zepbound, was no longer in shortage ...

PBMs are putting weight loss drugs, including Wegovy and Zepbound, on their national formularies, but coverage by plans is ...

Lilly has earmarked $200 million for the upgrade, a company spokesperson confirmed to Fierce Pharma. The new project will ...

The U.S. Food and Drug Administration on Friday agreed to reconsider a decision it made last month to bar drug compounders ...

With an estimated 2 million people in the United States taking copycat vers | A compounding industry group has sued the FDA, ...